Naproxen + Esomeprazole

Trade Name: 
Vimovo
Manufacturer/Distributor: 
AstraZeneca
www.astrazeneca.ca ; Medical Information 1-800-668-6000
Classification: 
NSAID + PPI
ATC Class: 
M01AE52 - naproxen and esomprazole
Status: 
active
Notice of Compliance (yyyy/mm/dd): 
2011/01/13
Date Marketed in Canada (yyyy/mm/dd): 
20011/01/14
Presentation: 
Tablet: 375 mg naproxen + 20 mg esomeprazole. DIN: 02361701
Tablet: 500 mg naproxen + 20 mg esomeprazole. DIN: 02361728
Comments: 
For treatment of signs and symptoms in patients with osteoarthritis, rheumatoid arthritis and ankylosing spondylitis and to decrease the risk of developing gastric ulcers in patients at risk for developing NSAID-associated gastric ulcers. The tablets contain an enteric-coated naproxen core and immediate-release esomeprazole film coat. The formulation is designed to release the active ingredients in a sequential manner: esomeprazole is rapidly released in the stomach, followed by the delayed release of naproxen in the small intestine.